USPTO serial 98843894
AMP2
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- GRAJEDA, HECTOR M
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with AMP2?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,246*
Plus Government fees of $600
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Frederick, MD, US
Frederick, MD, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
AARON D HENDELMAN
AARON D HENDELMAN WILSON SONSINI GOODRICH & ROSATI650 PAGE MILL ROADPALO ALTO, CA 94304UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | targetable bone morphogenetic proteins for use as an inducer of regenerative bone growth other than for medical or veterinary purposes | ACTIVE | — |
| 005 | Therapeutic proteins in the nature of bone morphogenetic proteins for use as a bone growth media for medical purposes, namely, the manufacture of implantable medical devices; Therapeutic proteins in the nature of bone morphogenetic proteins for medical use in vascular repair, orthopedic repair, bone repair, osteochondral repair, spinal fusion, dermal repair, soft tissue repair, extremities repair, craniomaxillofacial repair, chemotherapeutics, and sports medicine; pharmaceutical and medicinal preparations and substances for the treatment and prevention of bone and tissue diseases and disorders, musculoskeletal diseases and disorders, blood vessel diseases and damage, craniomaxillofacial diseases and damage, skin diseases and damage, bone and joint injuries, and cancer, namely, therapeutic proteins used for vascular repair, orthopedic repair, bone repair, osteochondral repair, spinal fusion, dermal repair, soft tissue repair, extremities repair, craniomaxillofacial repair, chemotherapeutics, and sports medicine; human allograft bone and tissue | ACTIVE | — |
| 010 | Implantable scaffolds comprising synthetic materials for maintaining tissue contour; implants consisting of synthetic materials; synthetic bone grafts; implants comprising natural, non-living materials; implantable scaffolds comprising synthetic materials, namely, fusion cages for spinal surgery and expandable spinal implants; bone void fillers comprised of synthetic materials; bone regeneration matrices being artificial biomaterials for augmentation of bone for medical purposes; soft tissue regeneration matrices being surgical implants and mesh made of synthetic materials for use in soft tissue repair or the reconstruction of soft tissue deficiencies; implantable medical devices to regenerate, repair, or treat soft tissue and bone; medical and surgical devices, apparatus, and instruments for use in bone and joint surgery, regeneration, reconstruction, and augmentation; artificial biomaterials for augmentation of bone for medical purposes, namely, synthetic materials for use in bone and joint surgery, bone regeneration, and bone reconstruction; bone implants composed of synthetic materials; implantable synthetic materials for surgical repair, regeneration, reconstruction, and augmentation of human tissue; artificial biomaterials for augmentation of tissue for medical purposes, namely, non-living tissue substitutes for use in human tissue repair, regeneration, and reconstruction; synthetic implantable medical devices for the regeneration of bone defects | ACTIVE | — |
| 042 | Research and development in connection with protein therapies for use in pharmaceutical products in the fields of orthopedics, vascular repair, orthopedic repair, bone repair, osteochondral repair, spinal fusion, dermal repair, soft tissue repair, extremities repair, craniomaxillofacial repair, chemotherapeutics, and sports medicine; medical research and product development in the fields of biotechnology, drug discovery, pharmaceuticals, scientific research, and protein therapeutics; development of therapeutics, namely, pharmaceutical and medical therapies for use in vascular repair, orthopedic repair, bone repair, osteochondral repair, spinal fusion, dermal repair, soft tissue repair, extremities repair, craniomaxillofacial repair, chemotherapeutics, and sports medicine; scientific research and development in the fields of orthopedics, vascular repair, orthopedic repair, bone repair, osteochondral repair, spinal fusion, dermal repair, soft tissue repair, extremities repair, craniomaxillofacial repair, chemotherapeutics, and sports medicine; research and development of medical devices, apparatus, and implants for use in vascular repair, orthopedic repair, bone repair, osteochondral repair, spinal fusion, dermal repair, soft tissue repair, extremities repair, craniomaxillofacial repair, chemotherapeutics, and sports medicine | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Theradaptive, Inc.
- Other trademarks owned by Theradaptive, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named AMP2
- Prosecution event NOAM explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 27, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 17, 2026 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Sep 17, 2026 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Sep 17, 2026 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Mar 9, 2026 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Mar 4, 2026 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Oct 6, 2025 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Sep 9, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 9, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 3, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 8, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 8, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 8, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 8, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 8, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 12, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 12, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 12, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 6, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| May 4, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 8, 2024 | NWAP | NEW APPLICATION ENTERED | — |